Suppr超能文献

血浆尾加压素II与高血压风险之间的关联:一项前瞻性研究的结果

Association between Plasma Urotensin II and Risk of Hypertension: Findings from a Prospective Study.

作者信息

Xie Huijian, Wang Xinya, He Yan, Huang Daoyi, Qu Xinyuan, Jiang Yanbo, An Yan, Zhang Shaoyan, Zhang Mingzhi

机构信息

Department of Epidemiology, School of Public Health and Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, Medical College of Soochow University, Suzhou 215123, China.

Center for Disease Prevention and Control of Pudong New District, Shanghai 200120, China.

出版信息

Int J Hypertens. 2020 Jan 30;2020:3284769. doi: 10.1155/2020/3284769. eCollection 2020.

Abstract

Up to date, human urotensin II (UII) is the most potent vasoconstrictor in mammalian animals. To explore whether UII played an important role in the development of hypertension, we conducted a prospective study in Changshu city, China. The baseline investigation was carried out in 2007, and the first follow-up investigation was conducted in 2013. From the participants, we randomly obtained 2000 normotensive subjects aged 40 years and older without any severe disease at baseline and examined plasma UII and endothelin-1 (ET-1) with their blood samples at baseline. Logistic models were used to analyze the association between baseline UII, baseline ET-1, and newly occurring hypertension. In 1,819 subjects with complete data, 723 subjects developed into hypertensive in about five years. After adjusting some potential confounders, the odds ratio (95% confidence interval) for risk of hypertension comparing the highest with the lowest quartile of baseline UII was 0.888 (0.689-1.144). The role of UII in the development of hypertension was not found in the current study; therefore, further research studies should be conducted to explore the relationship between UII and hypertension.

摘要

迄今为止,人尾加压素II(UII)是哺乳动物中最有效的血管收缩剂。为了探讨UII在高血压发生发展中是否起重要作用,我们在中国常熟市进行了一项前瞻性研究。基线调查于2007年进行,首次随访调查于2013年进行。我们从参与者中随机选取了2000名40岁及以上的血压正常受试者,这些受试者在基线时无任何严重疾病,并在基线时采集他们的血样检测血浆UII和内皮素-1(ET-1)。采用逻辑模型分析基线UII、基线ET-1与新发高血压之间的关联。在1819名有完整数据的受试者中,约五年内有723名受试者发展为高血压患者。在调整了一些潜在混杂因素后,将基线UII最高四分位数与最低四分位数相比,高血压风险的比值比(95%置信区间)为0.888(0.689 - 1.144)。在本研究中未发现UII在高血压发生发展中的作用;因此,应开展进一步的研究来探讨UII与高血压之间的关系。

相似文献

3
Renal impairment, hypertension and plasma urotensin II.肾功能损害、高血压与血浆尾加压素Ⅱ。
Nephrol Dial Transplant. 2011 Feb;26(2):609-14. doi: 10.1093/ndt/gfq416. Epub 2010 Jul 9.
4
Effects of peripherally administered urotensin II and arginine vasotocin on the QT interval of the electrocardiogram in trout.
Comp Biochem Physiol C Toxicol Pharmacol. 2016 May-Jun;183-184:53-60. doi: 10.1016/j.cbpc.2016.01.006. Epub 2016 Feb 21.
8
Does cigarette smoking increase plasma urotensin II concentrations?吸烟会增加血浆尾加压素II浓度吗?
Eur J Clin Pharmacol. 2007 Mar;63(3):253-7. doi: 10.1007/s00228-006-0252-6. Epub 2007 Jan 25.

本文引用的文献

10
Exercise urotensin II dynamics in myocardial infarction survivors with and without hypertension.
Int J Cardiol. 2006 Jun 16;110(2):175-8. doi: 10.1016/j.ijcard.2005.07.008. Epub 2005 Sep 28.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验